Delays As Korea Grapples With Immuno-Oncology Drug Coverage
This article was originally published in PharmAsia News
Executive Summary
With some of the new immuno-oncology drugs have already been launched in South Korea, experts are emphasizing the need to rapidly reimburse the innovative and pricey cancer therapies to reduce patients’ financial burden, amid debate over the best way of calculating prices.
You may also be interested in...
Korea Takes Its First Step Reimbursing IO Drugs
Amid repeated calls industry, South Korea decides to pay for Keytruda and Opdivo in its first reimbursement of immuno-oncology drugs, albeit at limited scope. The government is poised to expand reimbursement of IO drugs going forward amid its plan to significantly expand health insurance coverage.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.